Ligand Pharmaceuticals announced that the FDA has granted Orphan Drug Designation for its Captisol-enabled Topiramate Injection for the treatment of partial onset or primary generalized tonic-clonic seizures in hospitalized epilepsy patients who are unable to take oral topiramate.

The Captisol-enabled Topiramate Injection formulation is designed to provide an intravenous or intramuscular option for hospitalized epilepsy patients unable to use oral topiramate.

Captisol-enabled Topiramate Injection has been studied in Phase 1 clinical trials.

Topiramate is sold by Janssen Pharmaceuticals, Inc. under the trade name Topamax and is currently only available as oral formulations.

For more information call (858) 550-7500 or visit